InflaRx IFRX 深 沪
已收盘 10-02 16:00:00 美东时间
1.72
+0.010
+0.58%
华盛通- 最 高1.80
- 今 开1.74
- 成交量 42.22万股
- 最 低 1.72
- 昨 收 1.71
- 总市值 2.53亿
- 52周最高 2.9489
- 市盈率 静 --
- 换手率 0.29%
- 52周最低 0.7984
- 委 比 53.22%
- 总股本 1.47亿
- 历史最高 53.10
- 量 比 1.19
- 振 幅 4.68%
- 历史最低 0.7113
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
InflaRx N.V. has been selected for a late-breaking poster session at the American Society of Nephrology’s Kidney Week 2026 in Denver, Colorado, USA. The session will focus on izicopan, a second-generation oral C5a Receptor 1 antagonist, demonstrating promising therapeutic potential in kidney disease models. Izicopan, an orally administered small molecule inhibitor of the C5a receptor, has shown anti-inflammatory effects in preclinical models and ...
10-02 11:30
InflaRx to Host Virtual Capital Markets Day
InflaRx N.V. will host a virtual Capital Markets Event on November 3, 2026, from 8:00 AM EST to 9:00 AM EST, featuring Peter A. Merkel, MD, MPH, and Prof. Dr. Jörg Köhl. The event will discuss ANCA-associated vasculitis (AAV), the evolving treatment landscape, and the potential of izicopan, an orally administered C5a receptor inhibitor, to improve the standard of care. Key topics include InflaRx's development strategy, clinical program updates, a...
09-21 11:30
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
Needham Initiates Coverage On InflaRx with Buy Rating, Announces Price Target of $8
Needham analyst Joseph Stringer initiates coverage on InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $8.
09-14 18:37
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6
Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.
08-07 20:30
Analysts’ Top Healthcare Picks: InflaRx (IFRX), CG Oncology, Inc. (CGON)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-07 05:20
InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.08) by 25 percent. This is a 58.33 percent increase over losses of $(0.24) per share from the same period last year.
08-06 19:33
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
InflaRx N.V., a biopharmaceutical company developing anti-inflammatory therapies targeting the complement system, will release its Q2 2026 financial and operational results on August 6, 2026, before market open. No conference call is scheduled. The company specializes in C5a and C5aR inhibitors, with lead programs izicopan and vilobelimab for inflammatory diseases. Founded in 2007, InflaRx has offices in Germany and the U.S.
07-30 11:30
InflaRx Mulls Feasibility For AAV In Europe
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessmen...
06-30 19:37
